Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology

Rhea-AI Summary

Trace Biosciences, a clinical-stage biotech focused on nerve-targeted imaging agents, announced a strategic investment from Axogen (NASDAQ: AXGN) as part of Trace's Series A financing. Axogen is described as a global leader in surgical solutions for peripheral nerve repair.

The proceeds are earmarked to advance Trace's Nerve Trace near-infrared fluorescence imaging technology, which provides real-time visualization of nerves during surgery. Trace's lead candidate, Nerve Trace Dx, received FDA IND clearance in December 2025 and has begun a Phase I trial evaluating safety and feasibility in surgical patients, with the new capital intended to support planned Phase II and III trials toward a potential NDA.

Positive

• Axogen makes strategic equity investment in Trace as part of Series A
• Funding earmarked to support Phase II and III trials of Nerve Trace
• Nerve Trace Dx has FDA IND clearance received in December 2025
• Phase I clinical trial underway to assess safety and feasibility in surgical patients

Negative

• None.

News Explained

Trace Biosciences says it has received Axogen’s strategic investment as part of a Series A round that is not presented as complete because additional investors are expected; no amount, ownership terms, or dilution effect is disclosed.

Market Context

Historical event 1046357 recorded a 6.6% 24-hour move after Axogen's first-quarter earnings. That pl...

Analysis

Historical event 1046357 recorded a 6.6% 24-hour move after Axogen's first-quarter earnings. That platform record frames this strategic investment alongside prior company news, while the active S-3ASR shelf remains a financing risk to monitor.

Key Figures

Announcement date: July 29, 2026 Clinical applications: 2 applications FDA IND clearance: December 2025 +2 more

5 metrics

Announcement date July 29, 2026 Strategic investment announcement

Clinical applications 2 applications Nerve Trace technology

FDA IND clearance December 2025 Nerve Trace Dx

Phase I trial Phase I Safety and feasibility in surgical patients

Planned trials Phase II and III Clinical trials supported by investment proceeds

Historical Context

5 past events · Latest: Jul 15 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 15	Earnings date notice	Neutral	-0.1%	Scheduled second-quarter 2026 results and conference call announcement
Apr 30	Healthcare conference	Neutral	+3.4%	Announcement of participation in the Bank of America healthcare conference
Apr 28	Q1 earnings report	Positive	+6.6%	Revenue growth, raised guidance, and positive free-cash-flow outlook
Apr 14	Earnings date notice	Neutral	+3.0%	Scheduled first-quarter 2026 results and investor conference call
Feb 24	Full-year earnings report	Positive	-8.1%	Revenue growth, FDA approval, public offering, and 2026 guidance

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent AXGN news produced both positive and negative 24-hour reactions, with positive earnings events showing mixed outcomes.

Key Terms

near-infrared fluorescence imaging, series a financing, investigational new drug (ind), phase ii and iii clinical trials, +1 more

5 terms

near-infrared fluorescence imaging technical

"Nerve Trace is a near-infrared fluorescence imaging technology designed"

A medical imaging technique that uses harmless near-infrared light and fluorescent dyes or markers to make tissues, blood vessels, or tumors glow so a special camera can see them in real time. It penetrates deeper than visible light and produces high-contrast images during procedures like surgery or diagnostic tests, helping clinicians locate structures that are otherwise hard to see. Think of it as using a glow-in-the-dark highlighter and a sensitive camera to reveal hidden details inside the body — information that can affect the commercial prospects of devices, drugs, and diagnostics.

series a financing financial

"The investment is part of Trace's Series A financing round"

A Series A financing is an early formal round of investment in a growing private company where outside investors provide significant capital in exchange for a stake in the business. It matters to investors because it helps set the company's market value, shows that professional backers believe the business can scale, and determines how much ownership current holders keep—similar to bringing in a partner to fund and accelerate a first big expansion.

investigational new drug (ind) regulatory

"received FDA clearance of its Investigational New Drug (IND) application"

An investigational new drug (IND) is a drug or biologic that is being tested but has not yet been approved for general use; it is the application and formal status that allows a company to begin human clinical trials under regulator oversight. Investors care because an IND marks the transition from lab work to human testing — like getting a permit to run real-world experiments — which creates important milestones, costs, timelines and regulatory risk that drive a development-stage company's value.

phase ii and iii clinical trials medical

"support Trace's Phase II and III clinical trials toward a New Drug Application"

Phase II and Phase III clinical trials are successive stages of testing a new drug or medical treatment in people: Phase II evaluates whether the treatment has the intended effect and what dose works in a modest-sized group of patients, while Phase III runs larger, often multi-center studies to confirm effectiveness, monitor side effects, and compare to standard care. For investors, results at these stages strongly influence the likelihood of regulatory approval, the size of the addressable market, and the risk and value of the company — like a small dress rehearsal (Phase II) followed by the full performance (Phase III) that determines whether the show can go on.

new drug application (nda) regulatory

"clinical trials toward a New Drug Application (NDA)"

A new drug application (NDA) is a formal request submitted to regulatory authorities to gain approval for a new medication to be sold and used by the public. It is a comprehensive review process that examines the drug’s safety, effectiveness, and manufacturing quality. For investors, an NDA approval can signal a potential breakthrough product and influence a company's stock value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PORTLAND, Ore., July 29, 2026 /PRNewswire/ -- Trace Biosciences, Inc., a clinical-stage biotechnology company developing nerve-targeted imaging agents, today announced it has received a strategic investment from Axogen, Inc. (NASDAQ: AXGN), the global leader in surgical solutions for restoration of peripheral nerve function, as its technology continues to advance through clinical development. The investment is part of Trace's Series A financing round with additional investors expected to join.

Nerve Trace is a near-infrared fluorescence imaging technology designed to provide direct, real-time visualization of nerves during surgery, including nerves that are otherwise obscured from view by surrounding tissue. The technology enables two clinically significant applications. First, by rendering nerves visible in real time, it allows surgeons to identify and avoid nerves that would otherwise be obscured from view during a broad range of surgical procedures. Second, in cases where a nerve has already been injured, it allows surgeons to localize and assess the nerve with greater precision, supporting more effective surgical repair. Trace's lead candidate, Nerve Trace Dx, received FDA clearance of its Investigational New Drug (IND) application in December 2025 and has began its Phase I clinical trial evaluating Nerve Trace's safety and feasibility in surgical patients. Proceeds from the investment will support Trace's Phase II and III clinical trials toward a New Drug Application (NDA).

"We're pleased to welcome Axogen, a company that shares our commitment to protecting nerve function, as a strategic partner in this next phase of our growth. This investment strengthens our ability to advance Nerve Trace through the clinical work ahead, giving surgeons visibility into nerves they've not been able to see before," said Connor Barth, Ph.D., Co-Founder and CEO of Trace Biosciences.

"Improving nerve care starts with being able to see the nerve. You can't treat what you can't see," said Michael Dale, President and CEO of Axogen, Inc. "This investment in Trace's technology is directly aligned with our mission of making restoration of peripheral nerve function an expected standard of care. Giving surgeons the ability to see nerves in real time, whether to protect them or to treat them, is foundational to that mission."

About Trace Biosciences

Trace Biosciences is a clinical-stage biotechnology company pioneering nerve-targeted imaging technologies for surgery. Founded by leaders in imaging, chemistry, and translational medicine, Trace is developing a new class of small-molecule imaging agents designed to make nerves visible and measurable in clinical settings. The company's mission is to make safe, precise surgery a reality by making nerves visible in every operating room.

For more information, visit www.trace-bio.com 

About Axogen, Inc

Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. Axogen's product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.

For more information, visit www.axogeninc.com 

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the terms and expected timing of the financing, the use of proceeds, the progress of clinical trials, and the anticipated benefits of the collaboration between Trace Biosciences and Axogen. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Trace Biosciences undertakes no obligation to update these statements except as required by law.

Media Contact: info@trace-bio.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/trace-biosciences-announces-strategic-investment-from-axogen-to-advance-clinical-development-of-its-nerve-trace-nerve-specific-imaging-technology-302835491.html

SOURCE Trace Biosciences

FAQ

What did Axogen (NASDAQ: AXGN) announce regarding Trace Biosciences and Nerve Trace?

Axogen announced a strategic investment in Trace Biosciences to support development of its Nerve Trace imaging technology. According to Trace Biosciences, the funding is part of its Series A round and is intended to advance clinical trials toward a potential New Drug Application.

What is Trace Biosciences' Nerve Trace technology and how is it used in surgery?

Nerve Trace is a near-infrared fluorescence imaging technology that provides direct, real-time visualization of nerves during surgery. According to Trace Biosciences, it helps surgeons avoid obscured nerves and precisely localize injured nerves, supporting more effective nerve-sparing procedures and surgical repair.

What stage of clinical development is Nerve Trace Dx in as of July 2026?

As of July 2026, Nerve Trace Dx is in a Phase I clinical trial evaluating safety and feasibility in surgical patients. According to Trace Biosciences, its FDA Investigational New Drug (IND) application was cleared in December 2025, enabling the current clinical study.

How will Axogen’s investment impact future Nerve Trace clinical trials?

Axogen’s investment is intended to fund Trace Biosciences’ planned Phase II and III clinical trials for Nerve Trace. According to Trace Biosciences, these trials are expected to support a future New Drug Application, advancing the nerve-visualization technology toward potential regulatory review.

What surgical benefits does Nerve Trace offer compared with standard visualization?

Nerve Trace offers direct, real-time fluorescence visualization of nerves, including those obscured by tissue, during surgery. According to Trace Biosciences, this may help surgeons avoid unintended nerve injury and more accurately locate and assess damaged nerves for targeted surgical repair.

Why is Axogen investing in Trace Biosciences’ nerve-specific imaging platform?

Axogen is investing because Trace Biosciences’ technology aligns with its mission of restoring peripheral nerve function. According to Axogen, real-time visualization of nerves to protect or treat them is foundational to improving nerve care and making nerve restoration an expected standard of care.